Bio-Path Holdings FY2023 net loss $16.1M; cash drops to $1.1M from $10.4M

BIO-PATH HOLDINGS, INC.

Net loss $16.1M ($33.63 per share) vs $13.9M ($38.12 per share) in FY2022.
Cash at Dec 31, 2023: $1.1M, down from $10.4M a year earlier.
R&D expense rose to $11.6M from $9.2M on manufacturing and trial enrollment.
Completed first dose cohort in Phase 1/1b trial of BP1002 for AML and Phase 1 trial for lymphoma/CLL.
G&A fell to $4.2M from $4.7M; net cash used in ops $11.5M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2023 results: net income $16.1 million, or $33.63 per share, EPS $33.63 per share.

Period: the year ended December 31, 2023
Net income: $16.1 million, or $33.63 per share
EPS: $33.63 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $16.1 million, or $33.63 per share, for the year ended December 31, 2023, compared to a net loss of $13.9 million, or $38.12 per share, for the year ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-002780

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.